View:
X4 Pharmaceuticals, Inc.
61 North Beacon Street, 4th Floor
Boston, MA 02134
61 North Beacon Street, 4th Floor
Boston, MA 02134
May 12, 2026
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Jessica Dickerson
Re: X4 Pharmaceuticals, Inc.
Registration Statement on Form S-3 (File No. 333-295597)
Ladies and Gentlemen:
X4 Pharmaceuticals, Inc. hereby respectfully requests that, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, the effectiveness of the above-referenced Registration Statement on Form S-3 be accelerated so that it will become effective on May 14, 2026, at 4:15 p.m., Eastern Time, or as soon as practicable thereafter, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time.
We request that we be notified of such effectiveness by a telephone call to Branden C. Berns of Gibson, Dunn & Crutcher at (415) 393-4631.
Sincerely,
X4 PHARMACEUTICALS, INC
By: /s/ David Kirske_________________
David Kirske
Chief Financial Officer and Secretary
Chief Financial Officer and Secretary
cc: Adam R. Craig, M.D., Ph.D., X4 Pharmaceuticals, Inc.
Ryan A. Murr, Gibson, Dunn & Crutcher LLP
Branden C. Berns, Gibson, Dunn & Crutcher LLP